Founded by scientists at Randox Laboratories UK headquarters, Biochip Array Technology is claimed to permit highly accurate and advanced drug testing in a range of forensic specimens.
Biochip Array Technology incorporates reputable ELISA principles by consolidating a number of drug assays onto a small biochip.
The core of the technology is the Randox biochip, a solid-state device onto which antibodies specific to different drug compounds are immobilised and stabilised.
Up to 97 drug metabolites can be detected simultaneously on Drugs of Abuse Array I+ (DoA I+), providing forensic toxicologists with a high level of information from a small amount of specimen.
Since its inception, Randox has continued to develop the patented biochip technology so that it is adaptable to various forensic settings.
Six drugs of abuse arrays allow detection of 170 drug metabolites, including illicit and prescription drugs.
Biochips are optimised for a range of forensic matrices, allowing the assays to be sensitive and specific.
Forensic applications include screening tissue homogenates during post-mortem analysis.
Central laboratories with a large remit can benefit from the range of fully automated Evidence analysers, while the Evidence Multistat provides rapid forensic testing at the point of collection, such as the morgue.
According to Randox, independent studies have established that biochip arrays reduce the number of false presumptive results in comparison to other commercial immunoassay systems, ensuring optimum laboratory performance.
